Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis

Wang, Haoyu; Yang, Ruiyuan; Jin, Jing; Wang, Zhoufeng; Liu, Weimin

doi:10.1371/journal.pone.0259784

Cited by 3 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy often results in pulmonary injuries in clinical practice, which is called radiation-induced lung injury (RILI) and is especially observed during tumor treatment [46] . Radiation-induced pulmonary or systemic inflammation and malnutrition may lead to the appearance and development of lung cancer, [47,48] whereas pulmonary fibrosis, the most severe form of RILI, also increases the risk and worsens the prognosis of lung cancer because of a decline in lung function and activation of some tumor-associated pathways [49,50] . In addition, radiation itself can also induce novel genomic alterations irrespective of the type of primary tumor, suggesting that the genetic impact could be another contributing factor [51] …”

Section: Discussionmentioning

confidence: 99%

Risk of second primary lung cancer in patients with thyroid cancer: a meta-analysis based on big population studies

Wang

Yang

et al. 2023

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

Background: Previous studies have revealed that the number of cancer survivors developing a second primary malignancy is increasing, especially among thyroid cancer patients, and lung cancer is still the main cause of cancer death. Therefore, we aimed to investigate the risk of second primary lung cancer (SPLC) in patients with thyroid cancer. Methods: We searched the PubMed, Web of Science, Embase, and Scopus databases up to November 24, 2021, for relevant research and merged the standardized incidence ratios (SIRs) and 95% confidence intervals (95% CIs) to evaluate the risk of developing SPLC in patients with thyroid cancer. Results: Fourteen studies involving 1,480,816 cases were included in our meta-analysis. The pooled result demonstrated that thyroid cancer patients may have a higher risk of SPLC than the general population (SIR = 1.21, 95% CI: 1.07–1.36, P < 0.01, I 2 = 81%, P < 0.01). Subgroup analysis stratified by sex indicated that female patients may have a markedly higher risk of SPLC than male patients (SIR = 1.65, 95% CI: 1.40–1.94, P < 0.01, I 2 = 75%, P < 0.01). Conclusions: Thyroid cancer patients are more likely to develop SPLC than the general population, especially women. However, other risk factors must be investigated, and more prospective studies are needed to confirm our results. Registration: International Prospective Register of Systematic Reviews: No. CRD42021285399.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of second primary lung cancer in patients with thyroid cancer: a meta-analysis based on big population studies

Wang

Yang

et al. 2023

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Mechanical forces: The missing link between idiopathic pulmonary fibrosis and lung cancer

Wang

Yang

2022

European Journal of Cell Biology

View full text Add to dashboard Cite

Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study

Mori,

Ueki,

Hasegawa

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objective Combined pulmonary fibrosis and emphysema (CPFE) is a syndrome characterized by the coexistence of emphysema and fibrotic interstitial lung disease (ILD). The aim of this study was to examine the effect of CPFE on lung cancer risk and lung cancer-related mortality in patients with rheumatoid arthritis (RA). Methods We conducted a multicenter retrospective cohort study of patients newly diagnosed with lung cancer at five community hospitals between June 2006 and December 2021. Patients were followed until lung cancer-related death, other-cause death, loss to follow-up, or the end of the study. We used the cumulative incidence function with Gray’s test and Fine-Gray regression analysis for survival analysis. Results A total of 563 patients with biopsy-proven lung cancer were included (82 RA patients and 481 non-RA patients). The prevalence of CPFE was higher in RA patients than in non-RA patients (40.2% vs.10.0%) at lung cancer diagnosis. During follow-up, the crude incidence rate of lung cancer-related death was 0.29 and 0.10 per patient-year (PY) in RA and non-RA patients, and 0.32 and 0.07 per PY in patients with CPFE and patients without ILD or emphysema, respectively. The estimated death probability at 5 years differed between RA and non-RA patients (66% vs. 32%, p<0.001) and between patients with CPFE and patients without ILD or emphysema (71% vs. 24%, p<0.001). In addition to clinical cancer stage and no surgery within 1 month, RA and CPFE were identified as independent predictive factors for increased lung cancer-related mortality (RA: adjusted hazard ratio [HR], 2.49; 95% confidence interval [CI], 1.65–4.76; CPFE: adjusted HR 2.01; 95% CI 1.24–3.23). Conclusions RA patients with lung cancer had a higher prevalence of CPFE and increased cancer-related mortality compared with non-RA patients. Close monitoring and optimal treatment strategies tailored to RA patients with CPFE are important to improve the poor prognosis of lung cancer.

show abstract

Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis

Cited by 3 publications

References 58 publications

Risk of second primary lung cancer in patients with thyroid cancer: a meta-analysis based on big population studies

Risk of second primary lung cancer in patients with thyroid cancer: a meta-analysis based on big population studies

Mechanical forces: The missing link between idiopathic pulmonary fibrosis and lung cancer

Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study

Contact Info

Product

Resources

About